WallStreetZenWallStreetZen

Stock IdeasStrong Buy Stocks
Strong Buy Stocks from Top Wall Street Analysts
Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Analyst / FirmCompanyPriceRatingPrice TargetUpside/DownsideDate
Vamil Divan
Guggenheim
Top 5%
96
Vera Therapeutics IncVERA
$43.83Strong Buy$56.00+27.77%
19 hours ago
Analyst Ranking
Top 5%
#215 out of 4527 analysts
Average Return
+15.72%
Win Rate
58%72 out of 125
Risk vs Reward
Poor
Good

Analyst Color

Guggenheim's Vamil Divan raised their price target on Vera Therapeutics (NASDAQ: VERA) by 107.4% from $27 to $56 on 2024/03/27. The analyst maintained their Strong Buy rating on the stock.

Divan explained that their price target move followed updated Guggenheim analysis and "talks with leading nephrologists."

The IgAN (IgA nephropathy or Berger disease) treatment market has seen "significant progress in recent years," the analyst detailed, and the key takeaway from the conversations with nephrologists was ramped sales estimates for Vera Therapeutics' atacicept.

Footnotes

From here: Atacicept is a recombinant fusion protein that contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases, such as IgA Nephropathy (IgAN) and lupus nephritis (LN). Blocking these cytokines with atacicept has been shown in clinical trials to reduce disease-causing antibodies.

Vera Therapeutics holds an exclusive worldwide license for the development and commercialization of atacicept in all indications from Merck KGaA.

Philippe Houchois
Jefferies
Top 19%
82
Tesla IncTSLA
$800.00Strong Buy$850.00+6.25%
a day ago

Upgrade to Premium to View More

Strong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts

Already have a premium account? Sign In
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.